Regulatory labeling stratifies use by PD-L1 status: monotherapy for PD-L1–negative/checkpoint-ineligible disease and combination with pembrolizumab (or Qlex) for PD ...
Venetoclax plus pediatric-inspired chemotherapy yielded an 87% post-induction response in adult T-ALL, with 75% MRD negativity among complete remissions and strong activity in ETP-ALL. Cytopenias were ...
Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...
New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.
In this episode, 'Epcoritamab in RRFL: Efficacy Data, Administration Considerations, and the Pharmacist's Operational Role,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions: In ...
In 'From Promise to Practice: Overcoming Access and Administration Challenges for Bispecifics in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical question: In 'From ...
From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...
FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...
Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and ...
CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident management assignment. Aboard MV Hondius, 12 confirmed and 1 probable Andes ...
Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results